Technivie Now Approved for Use

TechnivieTechnivie (ombitasvir/paritaprevir/ritonavir) with ribavirin  is now an approved hepatitis C treatment in Canada!

Health Canada has granted the treatment Technivie with ribavirin a Notice of Compliance (NOC) for treating adult patients with chronic hep C genotype 4 without cirrhosis and who have never tried treatment or who have previously been treated with pegylated interferon and ribavirin.

A Notice of Compliance

Receiving a Notice of Compliance allows a treatment to be sold in Canada with official approval. If a drug has a Notice of Compliance a doctor may prescribe it – but at this stage the new drug combination is still not available on public drug plans, like BC PharmaCare. Private insurers each decide company coverage of the new drug (i.e. what percentage of the drug costs they will cover).

For more information about Technivie (ombitasvir/paritaprevir/ritonavir), or any other new and emerging hep C drug, please visit PHCN’s Hepatitis C Treatment Information Project or email.